Yonhap News Agency on MSN6h
Celltrion gets U.S. approval for allergic asthma biosimilar
Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday its biosimilar for asthma and other chronic allergic diseases has obtained approval for U.S. sales. The U.S. Food and Drug ...
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...
The Pharma Letter20h
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...